Patient and disease characteristics
| . | Mismatched unrelated donor (N = 72) . | Matched unrelated donor (N = 193) . |
|---|---|---|
| Age and follow-up (range), y | ||
| Median age at time of transplantation | 60 (21-74) | 60 (23-76) |
| Median follow-up | 1.9 (0.2-10.1) | 2.1 (0.1-12.5) |
| Diagnosis | ||
| Lymphoid malignancies | 36 (50) | 104 (54) |
| Non-Hodgkin lymphoma | 16 (22) | 56 (29) |
| Diffuse large B-cell lymphoma | 5 (7) | 17 (9) |
| Follicular lymphoma | 4 (6) | 7 (4) |
| Mantle cell lymphoma | 2 (3) | 24 (12) |
| Other B-cell lymphoma* | 0 (0) | 3 (2) |
| T-cell lymphoma† | 5 (7) | 5 (3) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 12 (17) | 33 (17) |
| Classical Hodgkin lymphoma | 6 (8) | 10 (5) |
| Pre-B acute lymphoblastic leukemia | 2 (3) | 5 (3) |
| Prior autologous transplantation | 9/36 (25) | 34/104 (33) |
| Myeloid malignancies | 36 (50) | 89 (46) |
| Acute myeloid leukemia | 23 (32) | 59 (31) |
| De novo acute myeloid leukemia | 15 (21) | 40 (21) |
| Secondary acute myeloid leukemia‡ | 8 (11) | 19 (10) |
| Myelodysplastic syndrome and myeloproliferative neoplasms | 8 (11) | 27 (14) |
| Chronic myeloid leukemia | 5 (7) | 3 (2) |
| Prior autologous transplantation | 2/36 (6) | 0/89 (0) |
| Prior allogeneic transplantation | 1/36 (3) | 2/89 (2) |
| Disease risk index | ||
| Low risk | 5 (7) | 14 (7) |
| Intermediate risk | 34 (47) | 101 (52) |
| High risk | 30 (42) | 72 (37) |
| Very high risk | 3 (4) | 6 (3) |
| Comorbidity index | ||
| HCT-CI score 0 | 25 (35) | 78 (40) |
| HCT-CI score 1 | 16 (22) | 44 (23) |
| HCT-CI score 2 | 14 (19) | 28 (15) |
| HCT-CI score ≥3 | 17 (24) | 43 (22) |
| Sex mismatch | ||
| Male donor, male recipient | 23 (32) | 70 (36) |
| Male donor, female recipient | 14 (19) | 50 (26) |
| Female donor, male recipient | 22 (31) | 41 (21) |
| Female donor, female recipient | 13 (18) | 32 (17) |
| CMV serologic status | ||
| Donor and/or recipient seropositive | 54 (75) | 130 (67) |
| Donor and recipient seronegative | 18 (25) | 63 (33) |
| Disease status at the start of conditioning | ||
| Lymphoid malignancies | N = 36 | N = 104 |
| Complete remission | 16 (44) | 51 (49) |
| Partial remission | 16 (44) | 46 (44) |
| Stable disease or progressive disease | 4 (11) | 7 (7) |
| Myeloid malignancies | N = 36 | N = 89 |
| First complete remission | 22 (61) | 62 (70) |
| Second complete remission | 6 (17) | 8 (9) |
| Disease status beyond second complete remission | 8 (22) | 19 (21) |
| . | Mismatched unrelated donor (N = 72) . | Matched unrelated donor (N = 193) . |
|---|---|---|
| Age and follow-up (range), y | ||
| Median age at time of transplantation | 60 (21-74) | 60 (23-76) |
| Median follow-up | 1.9 (0.2-10.1) | 2.1 (0.1-12.5) |
| Diagnosis | ||
| Lymphoid malignancies | 36 (50) | 104 (54) |
| Non-Hodgkin lymphoma | 16 (22) | 56 (29) |
| Diffuse large B-cell lymphoma | 5 (7) | 17 (9) |
| Follicular lymphoma | 4 (6) | 7 (4) |
| Mantle cell lymphoma | 2 (3) | 24 (12) |
| Other B-cell lymphoma* | 0 (0) | 3 (2) |
| T-cell lymphoma† | 5 (7) | 5 (3) |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma | 12 (17) | 33 (17) |
| Classical Hodgkin lymphoma | 6 (8) | 10 (5) |
| Pre-B acute lymphoblastic leukemia | 2 (3) | 5 (3) |
| Prior autologous transplantation | 9/36 (25) | 34/104 (33) |
| Myeloid malignancies | 36 (50) | 89 (46) |
| Acute myeloid leukemia | 23 (32) | 59 (31) |
| De novo acute myeloid leukemia | 15 (21) | 40 (21) |
| Secondary acute myeloid leukemia‡ | 8 (11) | 19 (10) |
| Myelodysplastic syndrome and myeloproliferative neoplasms | 8 (11) | 27 (14) |
| Chronic myeloid leukemia | 5 (7) | 3 (2) |
| Prior autologous transplantation | 2/36 (6) | 0/89 (0) |
| Prior allogeneic transplantation | 1/36 (3) | 2/89 (2) |
| Disease risk index | ||
| Low risk | 5 (7) | 14 (7) |
| Intermediate risk | 34 (47) | 101 (52) |
| High risk | 30 (42) | 72 (37) |
| Very high risk | 3 (4) | 6 (3) |
| Comorbidity index | ||
| HCT-CI score 0 | 25 (35) | 78 (40) |
| HCT-CI score 1 | 16 (22) | 44 (23) |
| HCT-CI score 2 | 14 (19) | 28 (15) |
| HCT-CI score ≥3 | 17 (24) | 43 (22) |
| Sex mismatch | ||
| Male donor, male recipient | 23 (32) | 70 (36) |
| Male donor, female recipient | 14 (19) | 50 (26) |
| Female donor, male recipient | 22 (31) | 41 (21) |
| Female donor, female recipient | 13 (18) | 32 (17) |
| CMV serologic status | ||
| Donor and/or recipient seropositive | 54 (75) | 130 (67) |
| Donor and recipient seronegative | 18 (25) | 63 (33) |
| Disease status at the start of conditioning | ||
| Lymphoid malignancies | N = 36 | N = 104 |
| Complete remission | 16 (44) | 51 (49) |
| Partial remission | 16 (44) | 46 (44) |
| Stable disease or progressive disease | 4 (11) | 7 (7) |
| Myeloid malignancies | N = 36 | N = 89 |
| First complete remission | 22 (61) | 62 (70) |
| Second complete remission | 6 (17) | 8 (9) |
| Disease status beyond second complete remission | 8 (22) | 19 (21) |
Data are presented as n (%) unless otherwise indicated.
Other B-cell non-Hodgkin lymphoma includes 1 patient with nodal marginal zone lymphoma and 1 patient with lymphoplasmacytic lymphoma.
T-cell non-Hodgkin lymphoma includes 5 patients with angioimmunoblastic T-cell lymphoma, 2 patients with subcutaneous panniculitis-like T-cell lymphoma, 2 patients with peripheral T-cell lymphoma not otherwise specified, and 1 patient with anaplastic large cell lymphoma.
Secondary acute myeloid leukemia includes patients with an antecedent myelodysplastic syndrome or myeloproliferative neoplasm or therapy-related acute myeloid leukemia.